Tolerability, Safety and Efficacy of SAD448 in Subjects With Ocular Hypertension
NCT00503360
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
80
Enrollment
INDUSTRY
Sponsor class
Conditions
Ocular Hypertension
Interventions
DRUG:
SAD448
Sponsor
Novartis